Efficacy and Safety of Sacubitril/Valsartan in Hemodialysis Patients with Hypertension

Efficacy and Safety of Sacubitril/Valsartan in Hemodialysis Patients with Hypertension - Efficacy and Safety of Sacubitril/Valsartan in Hemodialysis Patients with Hypertension

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000049348

Enrollment

Registered

2022-11-01

Start date

2021-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-stage renal failure

Interventions

All patients were switched from angiotensin receptor II blocker to sacubitril/valsartan. Patients were initially instructed to take sacubitril/valsartan 50 mg once daily, and the dosage was gradually

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age 18 years and over 2. Receiving thrice-weekly maintenance hemodialysis with session length more than or equal to 3 hours. 3. Receiving maintenance hemodialysis for more than 90 days.

Exclusion criteria

Exclusion criteria: 1. Non-sinus rhythm 2. Life expectancy of less than one year 3. Apparent infection 4. Myocardial infarction and/or stroke within 30 days 5. Current pregnancy 6. Malignancy.

Design outcomes

Primary

Measure	Time frame
Comparison of blood pressure during hemodialysis after 3 months.	—

Secondary

Measure	Time frame
1. Change in home blood pressure 2. Change in liver function and electrolytes 3. Change in NT-proBNP	—

Countries

Japan

Contacts

Public ContactYoshio Iwashima

Kansai Medical University Kori Hospital Department of Internal Medicine

iwashimy@kouri.kmu.ac.jp0728325321

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026